-
Insulin glargine sold
under the
brand name
Lantus among others is a long-acting
modified form of
medical insulin, used in the
management of type 1 and...
-
Insulin glargine/lixisenatide, sold
under the
brand name
Soliqua among others, is a fixed-dose
combination medication that
combines insulin glargine and lixisenatide...
-
hours provided by
other marketed long-acting
insulins such as
insulin glargine and
insulin detemir),
making it a once-daily
basal insulin, that is one...
- product,
Semglee (insulin
glargine-yfgn), for the
treatment of diabetes.
Unbranded versions of
insulin glargine and
insulin glargine-yfgn are sold by Sanofi...
-
other type is long
acting insulin; the
first of
these was
Lantus (insulin
glargine).
These have a
steady effect for an
extended period from 18 to 24 hours...
-
approved insulin glargine-yfgn (Semglee), a
biosimilar product that
contains the long
acting analog insulin glargine.
Insulin glargine-yfgn is interchangeable...
- of Biocon's key
brands in
India include INSUGEN (rh-insulin),
BASALOG (
Glargine),
BIOMAb EGFR (Nimotuzumab),
BLISTO (Glimepiride + Metformin),
CANMAb (Trastuzumab)...
-
without peak) are:
Extended insulin zinc
insulin (Ultralente)
Insulin glargine (Lantus)
Insulin detemir (Levemir)
Insulin degludec (Tresiba)
Insulin degludec...
- was
superior to dulaglutide, semaglutide,
insulin degludec, and
insulin glargine in
improving blood sugar and obesity. In a
phase III double-blind, randomized...
-
after meals. Long-acting (basal)
insulin analogues,
including insulin glargine,
insulin detemir, and
insulin degludec,
provide a
sustained release of...
